Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOXIRI vs mFOLFOX6/CapeOx in Adjuvant Stage IIIB/IIIC Colorectal Cancer
NCT05200299Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05200299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200299.